Ranibizumab for Refractory Uveitis-related Macular Edema

American Journal of Ophthalmology

Volumn 148, Issue 2, 2009, Pages

  Acharya, Nisha R ^a,b   Hong, Kevin C ^a   Lee, Salena M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AZATHIOPRINE; CORTICOSTEROID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE CONTROL; DRUG EFFECT; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA CYSTOID EDEMA; SPECTACLES; THICKNESS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 67650453430     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.03.028     Document Type: Article

References (26)

1. Okhravi N., and Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm 11 (2003) 29-38
2. Nussenblatt R. Treating intraocular inflammatory disease in the 21st century. Arch Ophthalmol 123 (2005) 1000-1001
3. Gritz D.C., and Wong I.G. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111 (2004) 491-500
4. Nussenblatt R.B. The natural history of uveitis. Int Ophthalmol 14 (1990) 303-308
5. Jabs D.A., Rosenbaum J.T., Foster C.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130 (2000) 492-513
6. Lardenoye C.W., van Kooij B., and Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology 113 (2006) 1446-1449
7. Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 10 (2002) 239-246
8. Papadaki T., Zacharopoulos I., Iaccheri B., et al. Somatostatin for uveitic cystoid macular edema (CME). Ocul Immunol Inflamm 13 (2005) 469-470
9. Kok H., Lau C., Maycock N., et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 112 (2005) 1916.e1-1921.e7
10. Van Kooij B., Rothova A., and de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm 14 (2006) 73-85
11. Tranos P., Scott R., Zambarajki H., et al. The effect of pars plana vitrectomy on cystoid macular edema associated with chronic uveitis-A randomized, controlled pilot study. Br J Ophthalmol 90 (2006) 1107-1110
12. Gutfleisch M., Spital G., Mingels A., et al. Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol 91 (2007) 345-348
13. Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol 18 (2007) 487-492
14. Fine H.F., Baffi J., Reed G.F., et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 132 (2001) 794-796
15. Vinores S.A., Chan C.C., Vinores M.A., et al. Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol 89 (1998) 43-50
16. Cohen T., Nahari D., Cerem L.W., Neufeld G., and Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271 (1996) 736-741
17. Van Kooij B., Rothova A., Rijkers G.T., and de Groot-Mijnes J.D. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol 142 (2006) 192-194
18. Jabs D.A., Nussenblatt R.B., and Rosenbaum J.T. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140 (2005) 509-516
19. Androudi S., Letko E., Meniconi M., et al. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm 13 (2005) 205-212
20. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
21. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
22. Chun D.W., Heier J.S., Topping T.M., et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113 (2006) 1706-1712
23. Cordero Coma M., Sobrin L., Onal S., Christen W., and Foster C.S. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114 (2007) 1574-1579
24. Mackensen F., Heinz C., Becker M.D., and Heiligenhaus A. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 28 (2008) 41-45
25. Ferrara N., Damico L., Shams N., et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 (2006) 859-870
26. Markomichelakis N.N., Halkiadakis I., Pantelia E., et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 111 (2004) 946-953